Bioenvision to Hold Fiscal 2005 Year-End Financial Results Conference Call Tuesday, September 27, 2005

Bioenvision (NASDAQ NM: BIVN) will release fiscal 2005
year-end financial results before the market opens on Tuesday,
September 27, 2005.
   Christopher B. Wood, M.D., chairman and CEO of Bioenvision, and
David P. Luci, CFO and general counsel, will host an investment
conference call beginning at 8:00 a.m. Eastern Daylight Time on
Tuesday, September 27, 2005 to discuss these results and to answer
questions.
   To participate in the live call by telephone, please dial
877-825-5811 from the U.S. and Canada or 973-582-2767 from outside the
U.S and Canada. A telephone replay of the call will be available
beginning at 10 a.m. EDT September 27, 2005 through midnight on
October 4th, 2005 by dialing 877-519-4471 (U.S. or Canada) or
973-341-3080 (outside the U.S./ Canada) and entering reservation
number 6517269.
   Those interested in listening to the conference call live via the
Internet may do so by visiting Bioenvision's web site at
www.bioenvision.com. To listen to the live call, please go to the web
site 15 minutes prior to its start to register, download, and install
the necessary audio software. A replay of the call will be available
on the web site for 14 days.

   About Bioenvision

   Bioenvision's primary focus is the acquisition, development and
distribution of compounds and technologies for the treatment of
cancer. Bioenvision has a broad pipeline of products for the treatment
of cancer, including: Clofarabine (in co-development with Genzyme
Corporation), Modrenal(R) (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products in clinical trials.
Bioenvision is also developing anti-infective technologies, including
the OLIGON technology; an advanced biomaterial that has been
incorporated into various FDA approved medical devices. For more
information on Bioenvision please visit our web site at
www.bioenvision.com.

   Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.